State of the Art HIFU Technology for Prostate Cancer: Sonablate 450
The Sonablate® 450 is a state-of-the-art, minimally invasive HIFU device developed by Sonacare for the treatment of localized prostate cancer. It is the first High Intensity Focused Ultrasound (HIFU) device to receive FDA regulatory authorization for prostate tissue ablation.
The device obtains real-time ultrasound images of the prostate and surrounding areas. These images allow Dr. Gapin to plan precisely where the ultrasound energy will be delivered. The ultrasound energy is then directed on the cancerous prostate tissue leaving nearby healthy tissue intact.
Unlike radiation, HIFU is non-ionizing so it can be repeated, if necessary, without damaging healthy tissue. It may also be used as a salvage technique in the event that other prostate treatments fail.
Sonablate is the only HIFU therapy device for prostate cancer that does not require a transurethral resection of the prostate (TURP), prior to treatment in order to achieve effective results.
|The Sonablate450 is the only HIFU device for prostate cancer that:|